Australia Oncology Companion Diagnostic Market Size & Outlook
Related Markets
Australia oncology companion diagnostic market highlights
- The Australia oncology companion diagnostic market generated a revenue of USD 80.9 million in 2023 and is expected to reach USD 173.7 million by 2030.
- The Australia market is expected to grow at a CAGR of 11.5% from 2024 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2023.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
Oncology companion diagnostic market data book summary
| Market revenue in 2023 | USD 80.9 million |
| Market revenue in 2030 | USD 173.7 million |
| Growth rate | 11.5% (CAGR from 2024 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | Agilent Technologies Inc, Illumina Inc, Qiagen NV, Thermo Fisher Scientific Inc, ARUP Laboratories, Abbott Laboratories, Myriad Genetics Inc, BioMerieux SA, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, Australia accounted for 1.7% of the global oncology companion diagnostic market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan oncology companion diagnostic market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 448.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Companion Diagnostic Market Scope
Oncology Companion Diagnostic Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| ARUP Laboratories | View profile | 1001-5000 | Salt Lake City, Utah, United States, North America | http://www.aruplab.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Agilent Technologies Inc | View profile | 17700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | https://www.agilent.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
| BioMerieux SA | View profile | 13982 | Marcy l’Etoile, Lyon, France, 69280 | http://www.biomerieux.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
| Roche Holding AG ADR | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
Australia oncology companion diagnostic market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology companion diagnostic market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 66.5% in 2024. Horizon Databook has segmented the Australia oncology companion diagnostic market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
The oncology companion diagnostic market in Australia is expected to grow significantly due to research collaborations and favorable government initiatives. In May 2022, the Australian Cancer Research Foundation (ACRF) launched the Child Cancer Liquid Biopsy Program for children with cancer.
Under this program, simple blood tests provide information about changes in a child with cancer and evaluate the treatment. Thus, Liquid biopsy enables the early detection of cancer and the monitoring of disease progression with minimal invasiveness. This improved diagnostic capability can increase the use of CDx tests, which are often used to identify patients who will benefit most from targeted therapies.
Reasons to subscribe to Australia oncology companion diagnostic market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia oncology companion diagnostic market databook
-
Our clientele includes a mix of oncology companion diagnostic market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia oncology companion diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Australia oncology companion diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia Product - Oncology Companion Diagnostics Market, 2024 - 2030 (US$M)
Australia Oncology Companion Diagnostic Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
